Skip to main content

Table 1 Report of pulmonary resection of lung cancers in patients after EGFR-TKI treatment

From: Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review

 

Age

Sex

TNM classification

Initial Stage

TKI

Surgical procedure

Pathological outcome

Complication

Outcome

Takamochi et al. 2007 [5]

73

F

cT2N2M1

IV

gefitinib

bilobectomy

pT1N0M1

 

no recurrence (2 months)

57

F

cT1N2M0

IIIA

gefitinib

lobectomy

CR

chylothorax

no recurrence (1.5 months)

Kappers et al. 2008 [6]

67

F

 

IIIA

erlotinib

lobectomy

near CR

 

unknown

Levchenko EV et al. 2009 [7]

62

F

 

IV

erlotinib

bilobectomy

EF 1a

 

meta in thorax (15 months)

48

M

 

IV

gefitinib

lobectomy

residual viable tumor

 

adrenal meta (5 months), DWD (8 months)

Shen et al. 2010 [9]

73

F

cT2N3M0

IIIB

gefitinib

lobectomy

alveolar cell carcinoma, N0

 

no recurrence (20 months)

Hishida et al. 2010 [8]

73

F

cT4N2M0

IIIB

gefitinib

lobectomy

pT2N1M0

 

bone meta (6 months), DWD (17 months)

63

F

cT2N3M1

IV

gefitinib

lobectomy

pT1N2M0

 

brain meta (5 months), AWD (24 months)

33

F

cT4N0M0

IIIA

gefitinib

extra pleural pneumonectomy

pT4N2M0

 

brain meta (3 months), DWD (19 months)

54

M

cT4N3M1

IV

gefitinib

lobectomy

pT4N0M0

 

meta in thorax (6 months), AWD (10 months)

71

F

cT2N3M0

IIIB

gefitinib

lobectomy

pT2N2M0

 

meta in thorax (4 months), DWD (21 months)

57

F

cT4N0M1

IV

gefitinib

lobectomy

pT2N0M0

 

unknown

Liu et al. 2011 [10]

64

F

cT2bN2M1

IV

gefitinib

bilobectomy

CR

 

no recurrence (21 months) Hashimoto et

Hashimoto et al. 2012 [12]

66

F

cT4N1M1a

IV

gefitinib

lobectomy

pT2aN0M0 StageIB

 

no recurrence (12 months)

Ong et al. 2012 [11]

78

F

cT3N2M0

IIIA

erlotinib

lobectomy

residual viable tumor, N0

 

meta in thorax (10 months)

Funakoshi et al. 2012 [14]

69

F

cT2aN0M0

IB

gefitinib

pneumonectomy

pT2aN0M0 StageIB

empysma

no recurrence (26 months)

Marech et al. 2013 [13]

67

F

cT4N2M0

IIIB

gefitinib

lobectomy

pT1N0M0

 

no recurrence (7 months)

Lopez-Gonzales et al. 2013 [15]

66

F

cT4N2M0

IIIB

gefitinib

pneumonectomy

<10% of residual viable tumor

 

brain meta (17 months), AWD (22 months)

Hishida et al. 2014 [4]

62

F

cT2aN2M0

IIIA

gefitinib

lobectomy

EF 1a

 

no recurrence (36 months)

51

F

cT2N3M1

IV

gefitinib

lobectomy

pT1N0M0, EF0

 

brain meta (2 months), AWD (94 months)

58

F

cT1bN0M1a

IV

gefitinib

bilobectomy

pT1N1M0, EF1a

 

meta in thorax (14.4 months), AWD (63 months)

58

F

cT2N2M0

IIIA

gefitinib

pneumonectomy

CR

 

brain meta (28 months), DWD (68 months)

Our two cases. 2017

72

F

cT2N2M0

IIIA

gefitinib

lobectomy

pT1N2M0, EF 1b

 

brain meta (8 months), DWD (18 months)

68

F

cT3N2M0

IIIA

afatinib

bilobectomy

pT1N0M0, EF 2a

 

bone meta (8 months), AWD (14 months)

  1. DWD died with disease, AWD alive with disease, CR complete response